CERVICAL CANCER METASTATIC
Clinical trials for CERVICAL CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new CERVICAL CANCER METASTATIC trials appear
Sign up with your email to follow new studies for CERVICAL CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Large study tests new drug combinations for advanced cervical cancer
Disease control Not yet recruitingThis study aims to observe the safety and effectiveness of treatments involving the drugs camrelizumab or famitinib for women with recurrent or metastatic cervical cancer. It will follow about 1,300 patients who have already decided to receive one of these treatments as part of t…
Matched conditions: CERVICAL CANCER METASTATIC
Sponsor: Qi Zhou • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for women with Tough-to-Treat cervical cancer
Disease control Not yet recruitingThis study is testing whether a new drug combination (WX390 plus toripalimab) works better than standard treatments for women with advanced cervical cancer that has returned or spread after previous platinum-based therapy. The trial will involve 440 participants across multiple c…
Matched conditions: CERVICAL CANCER METASTATIC
Phase: PHASE3 • Sponsor: Shanghai Jiatan Pharmatech Co., Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New drug combo trial seeks better tolerability for Tough-to-Treat cervical cancer
Disease control Not yet recruitingThis study is testing if using a lower dose of the drug famitinib, when combined with another drug called camrelizumab, can reduce side effects while still controlling cancer growth. It will involve 120 women with cervical cancer that has returned or spread and is no longer curab…
Matched conditions: CERVICAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC